Search clinical trials for: BIII 890 CL

Total 2975 results

Boehringer Ingelheim

Completed

Relative Bioavailability, Safety and Tolerability of Two Tablet Formulations of BIIL 284 BS

Healthy
AbbVie

Terminated

Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy Participants

Healthy Volunteers

United States
Brii Biosciences Limited
VBI Vaccines Inc.; Vir Biotechnology, Inc.

Completed

Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic HBV Infection

Hepatitis B, Chronic

Australia, China, Korea, Republic of, New Zealand, Singapore, Thailand
CSL Behring

Completed

An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A

Hemophilia A

United States, Australia, Austria, Canada, Czech Republic, Germany, Hungary, Italy, Japan, Lebanon, Malaysia, Netherlands, Philippines, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine, United Kingdom
Boehringer Ingelheim

Completed

Effect of Treatment With BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive
Bayer

Completed

Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980

Hemophilia A

United States
Medical University of Graz

Active, not recruiting

Factor XIII Activity in Gastrointestinal Bleedings

Gastro Intestinal Bleeding

Austria
Novo Nordisk A/S

Enrolling by invitation

A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan

Congenital Bleeding Disorder | Congenital FXIII Deficiency

Japan
Boehringer Ingelheim

Completed

Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy Volunteers

Hepatic Insufficiency
University of Ljubljana, Faculty of Medicine

Completed

Closed-Loop With Faster Aspart in Young Adults With Type 1 Diabetes

Type 1 Diabetes Mellitus

Slovenia
National Institute of Mental Health (NIMH)

Completed

Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder

Major Depression

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.

Hemophilia A

China
University of Pittsburgh
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A

Severe Hemophilia A

United States
Bayer

Completed

Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment (ECHO)

Hemophilia A

United States, Japan, United Kingdom, Spain
Nantes University Hospital

Terminated

Bone Demineralization Lesions in the Injured Marrow: Efficacy and Tolerability of Administration Early and Repeated the Zoledronic Acid. Comparative Study, Prospective, Double-blind Controlled (DBMZol) (DBMZol)

Bone Demineralization Lesions in the Injured Marrow

France
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors (HAVEN 3)

Hemophilia A

Australia, Taiwan, Korea, Republic of, France, Germany, Italy, South Africa, Spain, United States, Japan, Ireland, Poland, United Kingdom, Costa Rica
Bayer

Completed

Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A." (POTTER 10)

Hemophilia A

Italy
Bayer

Completed

Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery (NO PEACKS)

Hemophilia A

Germany, Spain, Austria, Italy, Slovenia, Greece, Netherlands
Bayer

Completed

Kogenate FS Regulatory Post-Marketing Surveillance (KG0910KR)

Hemophilia A

Korea, Republic of
Bayer

Completed

BAY81-8973 Pediatric Safety and Efficacy Trial

Haemophilia A

Spain, Russian Federation, United States, Hungary, Italy, Mexico, Norway, Romania, Bulgaria, Canada, Argentina, Denmark, Israel, Poland, Ireland, Latvia, Lithuania
Grifols Therapeutics LLC
Grifols Biologicals, LLC

Terminated

Alphanate in Immune Tolerance Induction Therapy

Hemophilia A, Congenital

United States, Spain, Italy, India, Canada, Russian Federation
Bioverativ Therapeutics Inc.

Completed

Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A

Severe Hemophilia A

United States, Hong Kong, Israel
Bio Products Laboratory

Completed

A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.

Von Willebrand Disease

Poland, United Kingdom
Bio Products Laboratory

Completed

An Open Study to Investigate the Safety and Efficacy of Optivate® in Haemophilia A Patients Undergoing Surgery.

Haemophilia A

Poland, United Kingdom
Bio Products Laboratory

Completed

An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.

Haemophilia A

United Kingdom, Poland
Novo Nordisk A/S

Completed

A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543

Congenital Bleeding Disorder | Haemophilia A

Japan
Bayer

Completed

A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A

Hemophilia A

China
University of Cambridge
Diabetes UK

Completed

Closing the Loop in Adults With Type 1 Diabetes in the Home Setting

Type 1 Diabetes Mellitus

United Kingdom
Octapharma

Terminated

Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq (PREVAIL)

Hemophilia A

Canada
Sonova AG

Completed

Quality Control of CE-Certified Phonak Hearing Aids - 2018_28

Hearing Loss | Sensorineural Hearing Loss

Switzerland
PX'Therapeutics
European Commission

Completed

EuroNeut41: Safety & Immunogenicity of Immunisations With HIV Vaccine

HIV

United Kingdom
Novo Nordisk A/S

Completed

Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725 (mentor™2)

Congenital Bleeding Disorder | Congenital FXIII Deficiency

France, United States, Israel, Spain, Switzerland, Germany, Canada, Japan, United Kingdom, Italy, Finland, Austria
Novo Nordisk A/S

Completed

Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects

Healthy | Congenital Bleeding Disorder | Congenital FXIII Deficiency

United Kingdom
Boehringer Ingelheim

Completed

The Effect of BIIL 284 BS on Induced-sputum Variables in Patients With Bronchial Asthma

Asthma
Boehringer Ingelheim

Completed

Effect of BIIL 284 BS on Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Terminated

Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric Patients

Cystic Fibrosis

United States
Rose Research Center, LLC
Foundation for a Smoke Free World INC

Completed

Exploratory Study of Switching From Combustible Cigarettes to the BIDI E-cigarette

Smoking Cessation

United States
Novo Nordisk A/S

Completed

Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study (mentor™6)

Congenital Bleeding Disorder | Congenital FXIII Deficiency

Spain, United States, Canada, Italy, United Kingdom, Hungary
Novo Nordisk A/S

Completed

Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency (mentor™5)

Congenital Bleeding Disorder | Congenital FXIII Deficiency

United Kingdom, Israel, United States
Fondazione Angelo Bianchi Bonomi
Sintesi Research Srl

Completed

Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET)

Hemophilia A

United States, India, Spain, Argentina, Austria, Brazil, Chile, Egypt, Iran, Islamic Republic of, Italy, Mexico, Saudi Arabia, South Africa, Turkey
University Hospital, Strasbourg, France

Completed

Effects of O2 and/or CO2 Inhalation on Rest and Exercise Pulmonary Hemodynamic (H2PAP)

Hypercapnia | Pulmonary Vascular Sensibility in Hypoxia | Hypoxia and Hypercapnia

France
Bio Products Laboratory

Completed

A Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Haemophilia A.

Haemophilia A

Poland
Bayer

Completed

Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients (OPTIMS)

Haemophilia A

France, Italy
Bayer

Completed

Prophylaxis Versus on Demand Treatment for Children With Hemophilia A

Hemophilia A

China
Bayer

Completed

Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America

Hemophilia A | Blood Coagulation Disorders

Mexico, Venezuela
Bayer

Completed

Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A

Blood Coagulation Disorders | Hematologic Disease

United States, Germany, United Kingdom, Canada
Boehringer Ingelheim

Completed

Pharmacokinetics, Safety and Efficacy of BIIL 284 BS in Patients With Rheumatoid Arthritis (RA)

Arthritis, Rheumatoid
Bayer

Completed

EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS

Hemophilia A

Croatia, Germany, Saudi Arabia, Kazakhstan, Romania, Russian Federation, Slovenia, Bahrain, United Arab Emirates, Bosnia and Herzegovina, Israel, Kuwait, Libyan Arab Jamahiriya, Morocco, Oman, Qatar, Tunisia
Bayer

Completed

Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222

Hemophilia A

Bulgaria
Bayer

Completed

Prophylaxis Versus On-demand Therapy Through Economic Report (POTTER)

Hemophilia A

Italy

3

Subscribe